Clinical Trials Logo

Clinical Trial Summary

The goal of the proposed pilot study is to evaluate the feasibility of a new leg heat therapy system treatment for patients with lower extremity PAD. The new system is comprised of leg-length water circulating pads surrounded by a separate pneumatic compression outer garment that compresses the pads against the skin for efficient heat transfer. The new leg garment is easily closed with a zipper. The air chambers automatically adjust the amount of air inflation enabling use of the garment independent of patient leg size. Six patients with PAD will be asked to complete daily (90 min/day) home-based leg HT for 12 weeks using the newly developed system. The primary study outcome is the change from baseline in walking performance on the 6-minute walk test at the 12-week follow-up. Secondary outcomes include plantar flexion power, as assessed using isokinetic dynamometry, sit-to-stand muscle power and perceived quality of life.


Clinical Trial Description

Lower-extremity PAD is a manifestation of systemic atherosclerosis associated with increased risk of cardiovascular morbidity and mortality, diminished quality of life, physical functioning and psychological well-being. In 2015, an estimated 236 million people worldwide, most between 65 and 69 years of age, were living with PAD. Home-based leg heat therapy (HT) is emerging as a potential effective and practical treatment to increase leg blood flow and improve walking performance in patients with symptomatic PAD. In the first randomized sham-controlled trial to examine the benefits of supervised leg HT in patients with symptomatic PAD (90 min, 3 days/week for 6 weeks), we demonstrated that patients assigned to the leg heating group displayed a clinically meaningful improvement in perceived physical functioning. Building upon these findings, we recently completed a NIH-sponsored randomized clinical trial to examine the safety, tolerability, and effectiveness of home-based, unsupervised leg HT (90 min, 7 days/week for 8 weeks) in 34 patients with symptomatic PAD. Patients randomized to the HT group displayed an increase in 6-minute walk from baseline of 23 meters after 8 weeks of treatment, which is clinically meaningful for PAD patients. Importantly, home-based leg HT was also found to be safe (no skin injury), well-tolerated, and patient compliance was surprisingly high (96% completion of the prescribed treatment sessions). Heat packs, electric heating pads, and electric blankets are widely available, but have high risk of contact burns, particularly in patients with peripheral neuropathy that is commonly associated with diabetes mellitus and PAD. An assembly of individual pads is difficult to apply and skin contact is unreliable. Water-circulating pads have been found to be safer than electric devices because they provide more reliable thermostatic control. PAD patients with diffuse bilateral disease often accompanied by neuropathy need a reliable system that is simple to operate, easy to put on, covers the entirety of both lower limbs and safely provides HT while avoiding skin injury. Currently, there is no commercially-available HT system for home-based therapy in elderly individuals, despite the documented benefits associated with repeated HT. To address this unmet clinical need, Aquilo Sports is developing a system that will monitor skin temperature and have an integrated shut-off feature to prevent skin burns, and record treatment sessions to confirm patient compliance. The system has undergone extensive independent validation testing and has been widely adopted by professional athletes. The garment is easily closed with a zipper and auto-adjusts pneumatically to different leg sizes. Our objective is to establish evidence to support the safety and feasibility of the redeveloped Aquilo system during repeated home-based treatment in patients with PAD. Our approach to testing our hypothesis will be to ask 6 patients with PAD to undergo daily home-based leg HT (90 min/day, 7 days/week) for 12 weeks. The length of the intervention (12 weeks) was selected as it is similar to: 1) the duration of previous studies with other HT modalities showing beneficial effects in patients with PAD, 2) the recommended minimal duration of exercise training interventions, the gold standard treatment for PAD. The primary study outcome is the change from baseline in walking performance on the 6-minute walk test at the 12-week follow-up. Secondary outcomes include plantar flexion power, as assessed using isokinetic dynamometry, sit-to-stand muscle power and perceived quality of life.The study coordinator will call patients weekly to record the occurrence of adverse events. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05335161
Study type Interventional
Source Purdue University
Contact Bruno Tesini Roseguini, Ph.D.
Phone 7654962612
Email brosegui@purdue.edu
Status Not yet recruiting
Phase Phase 1
Start date September 1, 2022
Completion date January 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A